About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Glioblastoma Platelet Activation Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02887417

Glioblastoma Platelet Activation Study

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti...

Lead sponsor: University Medicine Greifswald•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Medicine Greifswald

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype. Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•MR-morphological suspicion for glioblastoma
•informed consent

Exclusion Criteria

•no informed consent

Related studies

RECRUITINGPhase 1

Sonodynamic Therapy in Patients With Recurrent GBM

NCT06039709 · Recurrent Glioblastoma, Glioblastoma Multiforme, and more

RECRUITINGPhase 1/2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more

RECRUITINGPhase 1/2

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812 · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

RECRUITINGPhase 2

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

NCT06069726 · Recurrent Glioblastoma

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 1, 2017Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment21

Start dateJan 2016

Last updatedAug 1, 2017

Condition

Glioblastoma Circulating Platelet-monocyte Conjugates

Locations shown

Department of Neurosurgery

Greifswald

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 1, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions